Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelines

Latigo Biotherapeutics and BlossomHill Therapeutics, both based in California, have filed applications to list on the Nasdaq Global Select Market. Latigo aims to raise up to $285.2 million to advance a non‑opioid analgesic, while BlossomHill seeks up to $129.1 million to support its oncology pipeline.

The two offerings are slated for a July 20, 2026 debut, with ticker symbols LTGO and BLSM respectively. Neither company has disclosed the exact timing of closing the offerings or the final amount of capital they expect to secure.

Their IPOs join an active first half of 2026 in which eighteen biotech firms have already gone public, more than double the total from the previous year. If both offerings close, 2026 could become the busiest biotech IPO year since the pandemic‑driven surge of 2021.